Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does SECUKINUMAB Cause Device delivery system issue? 180 Reports in FDA Database

Visibly Younger Skin in Weeks

Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.

Discover Synevra

According to the FDA Adverse Event Reporting System (FAERS), 180 reports of Device delivery system issue have been filed in association with SECUKINUMAB (COSENTYX). This represents 0.1% of all adverse event reports for SECUKINUMAB.

180
Reports of Device delivery system issue with SECUKINUMAB
0.1%
of all SECUKINUMAB reports
0
Deaths
8
Hospitalizations

How Dangerous Is Device delivery system issue From SECUKINUMAB?

Of the 180 reports, 8 (4.4%) required hospitalization, and 3 (1.7%) were considered life-threatening.

Is Device delivery system issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for SECUKINUMAB. However, 180 reports have been filed with the FAERS database.

What Other Side Effects Does SECUKINUMAB Cause?

Drug ineffective (27,434) Psoriasis (21,976) Pain (15,244) Arthralgia (13,769) Fatigue (9,406) Psoriatic arthropathy (8,900) Pruritus (8,755) Malaise (8,570) Rash (8,023) Condition aggravated (7,536)

What Other Drugs Cause Device delivery system issue?

ALBUTEROL (9,509) SOMATROPIN (1,848) EXENATIDE (1,533) BUDESONIDE\FORMOTEROL (1,260) BUDESONIDE\FORMOTEROL\GLYCOPYRROLATE (1,181) BUDESONIDE\FORMOTEROL\GLYCOPYRRONIUM (523) LEVALBUTEROL (459) MOMETASONE FUROATE\OLOPATADINE (347) ABATACEPT (342) PEGFILGRASTIM (323)

Which SECUKINUMAB Alternatives Have Lower Device delivery system issue Risk?

SECUKINUMAB vs SELADELPAR LYSINE SECUKINUMAB vs SELEGILINE SECUKINUMAB vs SELENIUM SECUKINUMAB vs SELENIUM SULFIDE SECUKINUMAB vs SELEXIPAG

Related Pages

SECUKINUMAB Full Profile All Device delivery system issue Reports All Drugs Causing Device delivery system issue SECUKINUMAB Demographics